Background
==========

Acyclovir, valacyclovir (a pro-drug which is metabolized to acyclovir), and famciclovir are prescribed for the treatment of herpes zoster infection \[[@B1],[@B2]\]. These drugs are commonly prescribed to older adults who are at risk of dose-related adverse drug reactions, particularly neurotoxicity with delirium \[[@B3],[@B4]\]. In older patients with chronic kidney disease, the recommendation is to reduce the dose of these drugs to prevent systemic accumulation from reduced elimination (Table [1](#T1){ref-type="table"}) \[[@B5]-[@B12]\]. There have been many case reports and case series of reversible acute neurological symptoms, such as delirium, resulting in hospitalization soon after the initiation of acyclovir, valacyclovir, or famciclovir \[[@B13]-[@B20]\]. Whether preferential use of a low dose of the antiviral drug minimizes this risk is unknown. Therefore, we conducted this study of older patients with herpes zoster infection to investigate whether initiation of a higher rather than lower dose of an oral antiviral drug in the outpatient setting is associated with more adverse drug events (neurotoxicity, death) within 30 days of prescription. We also considered whether any association between dose and adverse events differed in the presence of chronic kidney disease.

###### 

Oral antiviral dosing for acute herpes zoster in popular drug prescribing references

                  **Higher dose (mg/day)**^**a**^   **Lower dose (mg/day)**^**a**^   **UpToDate recommendations (dose in mg/day)**\[[@B7]\]**-**\[[@B9]\]   **Compendium of pharmaceuticals and specialties (dose in mg/day)**\[[@B10]\]**-**\[[@B12]\]
  -------------- --------------------------------- -------------------------------- ---------------------------------------------------------------------- ---------------------------------------------------------------------------------------------
  Acyclovir                    4,000                            3,200                                               4,000                                                                              4,000
                                                                2,400                                CrCl 10--25 mL/min/1.73 m^2^: 2,400                                                CrCl 10--25 mL/min/1.73 m^2^: 2,400
                                                                1,600                                 CrCl \<10 mL/min/1.73 m^2^: 1,600                                                  CrCl \<10 mL/min/1.73 m^2^: 1,600
                                                                 800                                                                                                                                      
  Valacyclovir                 3,000                            2,000                                               3,000                                                                              3,000
                                                                1,500                                     CrCl 15--30 mL/min: 2,000                                                          CrCl 15--30 mL/min: 2,000
                                                                1,000                                      CrCl \<15 mL/min: 1,000                                                            CrCl \<15 mL/min: 1,000
                                                                 500                                                                                                                                      
  Famciclovir                  1,500                            1,000                                               1,500                                                                              1,500
                                                                 500                                      CrCl 40--59 mL/min: 1,000                                                     CrCl 40--59 mL/min/1.73 m^2^: 1,000
                                                                350^b^                                     CrCl 20--39 mL/min: 500                                                       CrCl 20--39 mL/min/1.73 m^2^: 500
                                                                                                            CrCl \<20 mL/min: 250                                                         CrCl \<20 mL/min/1.73 m^2^: 250

^a^Dose categories as defined in this study include 50 mg dose above or below the cut-points.

^b^A dose of 350 mg/day was used instead of 250 mg/day because it was more commonly dispensed in our region with \<20 patients being prescribed a dose of \<300 mg/day.

*Abbreviation: CrCl* Creatinine Clearance.

Methods
=======

Design and setting
------------------

We conducted this study at the Institute for Clinical Evaluative Sciences (ICES) according to a pre-specified protocol that was approved by the research ethics board at Sunnybrook Health Sciences Centre (Toronto, Canada). Participant informed consent was not required for this study. We conducted a retrospective, population-based, matched cohort study of older adults using linked healthcare databases in Ontario, Canada. Ontario has approximately 13 million residents, 2 million of whom are aged 65 years or older \[[@B21]\]. Residents have universal access to hospital care and physician services and those aged 65 or older have universal prescription drug coverage. The reporting of this study follows guidelines set out for observational studies (Additional file [1](#S1){ref-type="supplementary-material"}: Table S1) \[[@B22]\].

Data sources
------------

We ascertained patient characteristics, drug use, covariate information, and outcome data using records from six databases. We obtained vital statistics from the Registered Persons Database (RPDB), which contains demographic information on all Ontario residents ever issued a health card. We used the Ontario Drug Benefit (ODB) database to identify prescription drug use, including dispensing date, quantity of pills, dose, and number of days supplied. This database contains highly accurate records of all outpatient prescriptions dispensed to patients aged 65 years or older, with an error rate of less than 1% \[[@B23]\]. We identified diagnostic and procedural information on all hospitalizations and emergency room visits from the Canadian Institute for Health Information Discharge Abstract Database (CIHI-DAD) and the National Ambulatory Care Reporting System (NACRS), respectively. We obtained covariate information from the Ontario Health Insurance Plan (OHIP) database, which includes health claims for inpatient and outpatient physician services. We used the ICES Physician Database (IPDB) to ascertain antiviral drug prescriber information. Previously, we have used these databases to research health adverse drug events and health outcomes, including acyclovir-induced acute kidney injury \[[@B24]-[@B26]\]. With the exception of antiviral prescriber specialty and income quintile (missing in 14.5% and 0.4% of patients, respectively), the databases were complete for all variables used in this study. Given the ability of our databases to capture healthcare activity province-wide, the only loss to follow-up would be if patients emigrated from Ontario (a rate estimated to be less than 1% per year) \[[@B27]\]. The database codes used in the analysis are defined in Additional file [1](#S1){ref-type="supplementary-material"}: Table S2.

Patients
--------

We established a cohort of residents aged ≥66 years in Ontario, Canada who filled a new outpatient prescription with ≥7-day supply for oral acyclovir, valacyclovir, or famciclovir from April 2002 to December 2011, a period spanning 9 years. We restricted our analysis to those who had evidence of a herpes zoster diagnosis in the 90 days prior to or 30 days following the time of the prescription (database diagnosis codes presented in Additional file [1](#S1){ref-type="supplementary-material"}: Table S2). The date of the first eligible prescription for a study antiviral served as the index date for that patient and marked the start date of follow-up. We excluded the following patients from the analysis: i) those in their first year of eligibility for prescription drug coverage (age 65) to avoid incomplete medication records, ii) those living in long-term care facilities since residents may have frequent episodes of confusion or delirium for many reasons, iii) those with end-stage renal disease, iv) those who had a prescription for any antiviral in the prior 180 days in order to capture new usage, v) those who had a prescription for more than one type of antiviral on the index date in order to compare mutually exclusive groups, and vi) those who had a hospital admission or discharge on their index date or a hospital discharge in the prior two days to ensure these were new outpatient antiviral prescriptions (as patients continuing an antiviral treatment initiated in hospital would have their outpatient antiviral prescription dispensed on the same or next day of hospital discharge).

To select two groups of antiviral users that were well-balanced on the baseline characteristics we measured in this study, we matched each low-dose user with a high-dose user on a 1:6 basis using the following variables: age (within two years), sex, presence of chronic kidney disease, and type of antiviral prescribed (acyclovir, valacyclovir, or famciclovir). In Ontario, the validated algorithm for chronic kidney disease identifies older adults with a median estimated glomerular filtration rate (eGFR) of 38 mL/min per 1.73 m^2^ (interquartile range 27 to 52), whereas its absence identifies those with a median eGFR of 69 mL/min per 1.73 m^2^ (interquartile range 56 to 82) \[[@B28]\].

Antiviral dose
--------------

To align with recommendations in drug prescribing references, a higher dose of antiviral therapy was defined as at least 4,000 mg/day for acyclovir, 3,000 mg/day for valacyclovir, and 1,500 mg/day for famciclovir. A lower dose of antiviral therapy was defined as 3,200 mg/day, 2,400 mg/day, 1,600 mg/day or 800 mg/day for acyclovir, 2,000 mg/day, 1,500 mg/day, 1,000 mg/day, or 500 mg/day for valacyclovir, and 1,000 mg/day, 500 mg/day, or 350 mg/day for famciclovir (Table [1](#T1){ref-type="table"}).

Outcomes
--------

We followed all patients for 30 days after the index date for the assessment of two pre-specified outcomes. The primary outcome was hospital admission with evidence of an urgent computed tomography (CT) scan of the head within the first five days of admission (inclusive of any scans performed in the emergency room preceding an admission). Based on prospective studies of common clinical practice, neuroimaging is frequently used in the routine evaluation of patients who present to hospital acutely confused, even among those without focal neurological findings or head trauma \[[@B29]-[@B31]\]. Unlike diagnostic codes for acute delirium, the receipt of a CT scan of the head is well coded in our data sources (these codes have high sensitivity and specificity for receipt of the imaging as they are associated with physician reimbursement) \[[@B32]\]. We also expected urgent CT scans of the head conducted for reasons unrelated to antiviral dosing to occur at a similar frequency in higher and lower dose groups; therefore, not impacting estimates of difference in risk. We have used this outcome of urgent CT scans of the head in other population-based drug safety studies to characterize the risk of drug-induced delirium \[[@B33]\]. Our secondary outcome was all-cause mortality. Death is accurately coded in our data sources (sensitivity 94%, positive predictive value 100%) \[[@B34]\].

Statistical analysis
--------------------

We compared baseline characteristics between those prescribed a higher or lower antiviral dose using standardized differences \[[@B35]\]. This metric describes differences between group means relative to the pooled standard deviation and is considered a meaningful difference if greater than 10%. We estimated the odds ratio and 95% confidence intervals for inpatient CT scan of the head with higher antiviral dose compared to lower antiviral dose using conditional logistic regression analyses (accounting for matched sets). We interpreted odds ratios as relative risks which was appropriate given the low incidence of observed events. We examined the relative risk between higher dose and lower dose (referent dose) antiviral and each outcome first in the entire matched cohort and then in four pre-defined subgroups based on: age, sex, presence of chronic kidney disease, and antiviral type. We examined whether relative risks differed among subgroups using tests for interaction. We conducted all analysis with Statistical Analysis Software (SAS) version 9.2 (SAS Institute Incorporated, Cary, North Carolina, USA, 2008).

Results
=======

We identified 77,381 eligible older adults who were prescribed outpatient oral antiviral drug for the treatment of herpes zoster infection (higher dose, n = 73,383 versus lower dose, n = 3,998). After the match, there were a total of 27,132 eligible patients of which 23,256 (85.7%) received a higher antiviral dose and 3,876 (14.3%) received lower antiviral dose (referent dose). A diagram of the cohort selection is represented in Additional file [1](#S1){ref-type="supplementary-material"}: Figure S1. The baseline characteristics of patients before and after the match are presented in Table [2](#T2){ref-type="table"}. After the match, the baseline characteristics of the two dose groups were nearly identical (all standardized differences for 17 measured variables between the groups were ≤8%). The mean age was 77 years (standard deviation 7.1 years) and 63% were women. Three-quarters of the prescriptions were written by primary care physicians with 67% of prescriptions written for valacyclovir. Ophthalmologist prescribed \<1% of the antivirals and \<0.3% of patients had a diagnosis for herpes zoster involving the eye.

###### 

Baseline characteristics

                                      **Unmatched**   **Matched**                                          
  ---------------------------------- --------------- -------------- ------- --------------- -------------- -------
  Demographics                                                                                                 
  Age, years                          75.9 \[6.8\]    77.0 \[7.3\]   0.15    76.7 \[7.1\]    76.7 \[7.1\]     0
  Women                               45,613 (62.2)   2,541 (63.6)   0.03    14,682 (63.1)   2,447 (63.1)     0
  Year of cohort entry                                                                                         
   2002 - 2003                        11,318 (15.4)    514 (12.9)    0.07    3,083 (13.3)     505 (13.0)    0.01
   2004 - 2005                        14,016 (19.1)    595 (14.9)    0.11    4,096 (17.6)     572 (14.8)    0.08
   2006 - 2007                        14,930 (20.3)    807 (20.2)      0     4,641 (20.0)     779 (20.1)      0
   2008 - 2009                        15,783 (21.5)    993 (24.8)    0.08    5,320 (22.9)     964 (24.9)    0.05
   2010 - 2011                        17,336 (23.6)   1,089 (27.2)   0.08    6,116 (26.3)    1,056 (27.2)   0.02
  Income quintile^d^                                                                                           
   First (lowest)                     13,937 (19.0)    831 (20.8)    0.04    4,404 (18.9)     804 (20.7)    0.05
   Second                             15,526 (21.2)    802 (20.1)    0.03    4,886 (21.0)     777 (20.1)    0.02
   Third (middle)                     14,231 (19.4)    842 (21.1)    0.04    4,469 (19.2)     818 (21.1)    0.05
   Fourth                             14,521 (19.8)    751 (18.8)    0.03    4,620 (19.9)     730 (18.8)    0.03
   Fifth (highest)                    14,976 (20.4)    755 (18.9)    0.04    4,808 (20.7)     731 (18.9)    0.05
   Missing                             192 (0.26)      17 (0.43)     0.03      69 (0.3)        16 (0.4)     0.02
  Rural location^e^                   10,864 (14.8)    505 (12.6)    0.06    3,027 (13.0)     491 (12.7)    0.01
  Modified Charlson score^f^                                                                                   
   0                                  53,431 (72.8)   2,731 (68.3)   0.10    16,623 (71.5)   2,684 (69.3)   0.05
   1                                  8,024 (10.9)     445 (11.1)    0.01    2,560 (11.0)     428 (11.0)      0
   2                                   6,350 (8.7)     400 (10.0)    0.05     2,086 (9.0)     383 (9.9)     0.03
   ≥3                                  5,578 (7.6)     422 (10.6)    0.10     1,987 (8.5)     381 (9.8)     0.04
  Co-morbidities^g^                                                                                            
   CKD^h^                              3,799 (5.2)     425 (10.6)    0.20     1,896 (8.2)     316 (8.2)       0
   Chronic liver disease               2,420 (3.3)     138 (3.5)     0.01      735 (3.2)      135 (3.5)     0.02
   COPD                                2,994 (4.1)     212 (5.3)     0.06     1,010 (4.3)     198 (5.1)     0.04
   CAD^i^                             25,840 (35.2)   1,548 (38.7)   0.07    8,427 (36.2)    1,478 (38.1)   0.04
   Diabetes mellitus^j^               11,016 (15.0)    699 (17.5)    0.07    3,636 (15.6)     671 (17.3)    0.05
   Heart failure                      8,469 (11.5)     611 (15.3)    0.11    2,985 (12.8)     571 (14.7)    0.06
   Stroke/TIA                          1,556 (2.1)     109 (2.7)     0.04      513 (2.2)       99 (2.6)     0.02
   Herpes zoster (eye)                  89 (0.12)       8 (0.20)     0.02      30 (0.13)       8 (0.21)     0.02
  Antiviral type                                                                                               
   Acyclovir                           4,095 (5.6)     297 (7.4)     0.08     1,692 (7.3)     282 (7.3)       0
   Valacyclovir                       29,482 (40.2)   2,694 (67.4)   0.57    15,528 (66.8)   2,588 (66.8)     0
   Famciclovir                        39,806 (54.2)   1,007 (25.2)   0.62    6,036 (26.0)    1,006 (26.0)     0
  Medications^k^                                                                                               
   Anticonvulsants                     3,079 (4.2)     178 (4.5)     0.01      988 (4.3)      167 (4.3)       0
   Gabapentin                          420 (0.57)      24 (0.60)       0      137 (0.59)      22 (0.57)       0
   Antidepressants                    11,201 (15.3)    663 (16.6)    0.04    3,756 (16.2)     636 (16.4)    0.01
   Antipsychotics                      1,431 (2.0)      88 (2.2)     0.02      503 (2.2)       86 (2.2)       0
   Barbituates                         115 (0.16)       7 (0.18)       0       45 (0.19)       7 (0.18)       0
   Benzodiazepines                    13,794 (18.8)    809 (20.2)    0.04    4,446 (19.1)     774 (20.0)    0.02
   Histamine2-receptor antagonists     6,191 (8.4)     337 (8.4)       0      1,911 (8.2)     325 (8.4)     0.01
   Dopamine agonists                   326 (0.44)      22 (0.55)     0.02     124 (0.53)      22 (0.57)       0
   Muscle relaxants                    399 (0.54)      25 (0.63)     0.01     132 (0.57)      25 (0.64)     0.01
   Opioids                            15,738 (21.5)    957 (23.9)    0.06    5,076 (21.8)     923 (23.8)    0.05
   Overactive bladder medications      2,169 (3.0)     149 (3.7)     0.04      704 (3.0)      142 (3.7)     0.04
  Prescribing physician                                                                                        
   General practitioner               55,723 (75.9)   3,015 (75.4)   0.01    17,671 (76.0)   2,925 (75.5)   0.01
   Ophthalmologist                     272 (0.37)      28 (0.70)     0.05      90 (0.39)      27 (0.70)     0.04
   Neurologist^l^                       41 (0.06)       ≤5 ( − )     ( − )     12 (0.05)       ≤5 ( − )     ( − )
   Other                              7,538 (10.3)     372 (9.3)     0.03    2,350 (10.1)     360 (9.3)     0.03
   Missing                            9,809 (13.4)     581 (14.5)    0.03    3,133 (13.5)     562 (14.5)    0.03

Data presented as number (percent) except for age which is presented as mean \[standard deviation\].

*Abbreviations: CAD* Coronary Artery Disease, *CKD* Chronic Kidney Disease, *COPD* Chronic Obstructive Pulmonary Disease, *TIA* Transient Ischemic Attack.

^a^Higher dose of antiviral defined as 4,000 mg/day for acyclovir, 3,000 mg/day for valacyclovir, and 1,500 mg/day for famciclovir.

^b^A lower dose of antiviral defined as 3,200 mg/day, 2,400 mg/day, 1,600 mg/day or 800 mg/day for acyclovir, 2,000 mg/day, 1,500 mg/day, 1,000 mg/day, or 500 mg/day for valacyclovir, and 1,000 mg/day, 500 mg/day, or 350 mg/day for famciclovir.

^c^Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a measure of the difference between groups divided by the pooled standardized difference; a value \>10% (0.1) is interpreted as a meaningful difference between the groups \[[@B35]\].

^d^Income was categorized into quintiles based on average neighbourhood income on the index date.

^e^Rural location indicates a population \<10,000.

^f^Assessed with an algorithm using diagnosis codes from hospitalizations in the five years prior; patients with no hospitalizations during this period were given a value of zero.

^g^Co-morbid diagnoses were ascertained from administrative database codes in the five years preceding the index date.

^h^Identified individuals with chronic kidney disease using an algorithm of diagnosis codes validated in our region for older adults \[[@B28]\]. The algorithm identified patients with a median estimated glomerular filtration rate (eGFR) of 38 mL/min per 1.73 m^2^ (interquartile range 27 to 52), whereas its absence identified patients with a median eGFR of 69 mL/min per 1.73 m^2^ (interquartile range 56 to 82).

^i^Coronary artery disease includes receipt of coronary artery bypass graft surgery, percutaneous coronary intervention, and diagnoses of angina.

^j^Identified individuals with diabetes through medication use including oral hypoglycemic and insulin.

^k^Medication use was assessed in the 180 days prior to the index date.

^l^Due to privacy issues, values ≤5 are suppressed.

Compared to lower antiviral dose, the initiation of higher antiviral dose was not associated with a higher risk of hospitalization with urgent CT scan of the head (247 \[1.06%\] events with higher dose versus 43 \[1.11%\] events with lower dose, relative risk 0.96, 95% confidence interval 0.69 to 1.33, p-value 0.79) (Table [3](#T3){ref-type="table"}). Figure [1](#F1){ref-type="fig"} presents the association between antiviral dose and the primary outcome in four pre-defined subgroups: by age, sex, presence of chronic kidney disease, and antiviral type. There was no association between antiviral dose and hospital admission with urgent CT scan of the head in any of the subgroups, including those with and without chronic kidney disease (p-value for interaction 0.25). There was also no difference between the two dose groups in the incidence of all-cause mortality (63 \[0.27%\] events with higher dose versus 15 \[0.39%\] events with lower dose, relative risk 0.70, 95% confidence interval 0.40 to 1.23, p-value 0.21) (Table [3](#T3){ref-type="table"}).

###### 

30-day outcomes of hospital admission with urgent CT scan of the head and all-cause mortality

                                                        **Number of events (Percent)**   **Relative risk**        **P-value**       
  ---------------------------------------------------- -------------------------------- ------------------- ----------------------- ------
  Hospital admission with urgent CT scan of the head             247 (1.06%)                43 (1.11%)       0.96 \[0.69 to 1.33\]   0.79
  All-cause mortality                                             63 (0.27%)                15 (0.39%)       0.70 \[0.40 to 1.23\]   0.21

Abbreviations: CT, Computed Tomography.

^a^Higher dose of antiviral defined as 4,000 mg/day for acyclovir, 3,000 mg/day for valacyclovir, and 1,500 mg/day for famciclovir.

^b^A lower dose of antiviral defined as 3,200 mg/day, 2,400 mg/day, 1,600 mg/day or 800 mg/day for acyclovir, 2,000 mg/day, 1,500 mg/day, 1,000 mg/day, or 500 mg/day for valacyclovir, and 1,000 mg/day, 500 mg/day, or 350 mg/day for famciclovir.

![Subgroup analysis of the risk of hospital admission with urgent CT scan of the head.](2050-6511-15-48-1){#F1}

Discussion
==========

In this population-based study of over 27,000 older patients, we found no association between initiating oral antiviral treatment for herpes zoster at a higher versus lower dose and the risk of hospital admission within 30 days with evidence of an urgent CT scan of the head. A similar association was observed in patients with and without chronic kidney disease, although given the smaller number of patients with chronic kidney disease, the estimates were less precise with wider confidence intervals. The 30-day risk of mortality was also no different between the two dose groups.

Acyclovir, valacyclovir, and famciclovir are commonly prescribed antivirals used in routine outpatient care for the treatment of herpes zoster infection in the elderly. In randomized controlled trials, these drugs are similarly effective in reducing the duration and severity of painful lesions, preventing complications, and decreasing the frequency of recurrence \[[@B1],[@B2]\]. A known adverse event of these oral antiviral drugs is neurotoxicity \[[@B13]-[@B20]\]. The symptoms of drug-induced neurotoxicity include tremor, confusion, hallucinations, and coma and can often be difficult to distinguish from herpes encephalitis. With these antivirals, symptoms typically occur within days of drug initiation and generally resolve with drug discontinuation. In one case series of 35 patients with neuropsychiatric symptoms during acyclovir treatment, risk factors included older age, the presence of chronic kidney disease, and co-administration of other potentially neurotoxic medications \[[@B13]\].

Given the results of these prior pharmacokinetic studies and case reports, we were concerned we would observe an increased risk of major adverse events when a higher rather than lower dose of an antiviral drug was initiated in older adults, particularly those with concomitant chronic kidney disease. The findings from this study are reassuring and support the safety of these drugs in older adults as currently prescribed in routine care.

Our study has a number of strengths. To our knowledge, it is the first population-based assessment of adverse outcomes from higher dose versus lower dose antiviral treatment. The study was made possible by our province's universal health care benefits, which provides information on all health care encounters for all Ontarians including accurate records of outpatient prescriptions to older patients. Consequently, there were a large number of patients who received antiviral prescriptions and this provided good precision for the estimates obtained for the primary outcome (there were over 200 events and the 95% confidence interval for the point estimate of the primary outcome was 0.69 to 1.33; confidently ruling out a 1.4 or higher risk).

Our study does have some limitations. For reasons of feasibility, in this retrospective study, we relied on urgent neuroimaging within the available data sources as a proxy for the diagnosis of acute altered mental status. A preferred methodology would be a prospective study with independent blinded outcome adjudication and detailed serial measures of cognitive function. In such an effort, kidney function values could also be recorded, rather than a validated algorithm for chronic kidney disease as used in our study. We were encouraged by the marked similarities in the baseline characteristics after matching and in the consistency of the observed association among various subgroups. However, in our study the antiviral dose was not randomly assigned, and with all observational studies, we may have failed to account for important unknown or unmeasured confounding variables. Our cohort consisted of patients over the age of 65 years. It is reassuring that 99% of elderly patients in routine care did not present to hospital with urgent CT scan of the head after use of either dose of oral antivirals. While we did not study younger patients in the present study, their incidence of adverse events would be expected to be even less.

Conclusions
===========

In this study, initiating a higher compared to a lower dose of an antiviral drug for the treatment of herpes zoster was not associated with an increased risk of adverse drug events. The findings support the safety of these drugs in older adults as currently prescribed in routine care.
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